SEC Form 4 · STOCK Act

Insider buys that paid off for the people who copied them.

$ZSTK

ZeroStack Corp.

+206.0%

Michael Heinrich, Executive Chair, bought $3.5M. Filed Jul 20, 6:31 PM ET.

COPIED JUL 21

$1,000 copied at the first price after the filing (Jul 21 open, $1.66) was $3,060 30 trading days later.

Example. Of 339 buys of $100K or more filed Jun 29 to Sep 11, the median lost 5.3% and 67.8% lost money over the same 30 trading days. Not investment advice.

Officers and directors must report their own stock purchases within two business days. We list every one, largest first, with what copying it would have returned.

A free account keeps a watchlist. No password: we email you a link.

NKTRSell

NEKTAR THERAPEUTICS

Howard W Robin · President and CEO

$30K−0.8%Aug 20
NKTRSell

NEKTAR THERAPEUTICS

Jonathan Zalevsky · Chief R&D Officer

$398K−36.8%Jul 2
NKTRSell

NEKTAR THERAPEUTICS

Howard W Robin · President and CEO

$1.2M−26.7%Jun 18
NKTRSell

NEKTAR THERAPEUTICS

Jonathan Zalevsky · Chief R&D Officer

$336K−26.4%Jun 17
NKTRSell

Nektar Therapeutics

Howard W Robin · President and CEO

$29K−1.0%May 21
NKTRSell

Nektar Therapeutics

Howard W Robin · President and CEO

$31K−1.0%Feb 20
NKTRSell

Nektar Therapeutics

Jonathan Zalevsky · Chief R, D Officer

$138K−15.0%Jan 22
NKTRSell

Nektar Therapeutics

Jonathan Zalevsky · Chief R, D Officer

$63K−6.0%Nov 25
NKTRSell

Nektar Therapeutics

Mark Andrew Wilson · General Counsel

$34K−3.0%Nov 25
NKTRSell

Nektar Therapeutics

Howard W Robin · President and CEO

$120K−4.0%Nov 25
NKTRSell

Nektar Therapeutics

Howard W Robin · President and CEO

$29K−2.0%May 20
NKTRSell

Nektar Therapeutics

Deep Track Capital, LP · 10% owner

$100KMay 13
NKTRSell

Nektar Therapeutics

Jonathan Zalevsky · Chief R, D Officer

$31K−3.0%Feb 17
NKTRSell

Nektar Therapeutics

Jillian B. Thomsen · CFO

$31K−3.0%Feb 17
NKTRSell

Nektar Therapeutics

Howard W Robin · President and CEO

$59K−2.0%Feb 17
NKTRSell

Nektar Therapeutics

Jonathan Zalevsky · Chief R, D Officer

$48K−4.0%Nov 18
NKTRSell

Nektar Therapeutics

Mark Andrew Wilson · General Counsel

$31K−3.0%Nov 18
NKTRSell

Nektar Therapeutics

Jillian B. Thomsen · CFO

$40K−3.0%Nov 18
NKTRSell

Nektar Therapeutics

Howard W Robin · President and CEO

$136K−4.0%Nov 18
NKTRSell

Nektar Therapeutics

Karin Eastham · Director

$77K−62.0%Sep 14
NKTRSell

Nektar Therapeutics

Jonathan Zalevsky · Chief R, D Officer

$343K−18.0%Aug 19
NKTRSell

Nektar Therapeutics

Jonathan Zalevsky · Chief R, D Officer

$50K−3.0%Aug 17
NKTRSell

Nektar Therapeutics

Howard W Robin · President and CEO

$65K−1.0%Aug 17
NKTRSell

Nektar Therapeutics

Jonathan Zalevsky · Chief R, D Officer

$86K−7.0%May 17
NKTRSell

Nektar Therapeutics

Howard W Robin · President and CEO

$144K−6.0%May 17
NKTRSell

Nektar Therapeutics

Gil M Labrucherie · SVP, COO and CFO

$69K−5.0%May 17
NKTRSell

Nektar Therapeutics

Jonathan Zalevsky · Chief R, D Officer

$119K−4.0%Feb 18
NKTRSell

Nektar Therapeutics

Mark Andrew Wilson · SVP and General Counsel

$40K−3.0%Feb 18
NKTRSell

Nektar Therapeutics

Jillian B. Thomsen · SVP and Chief Accounting Officer

$26K−1.0%Feb 18
NKTRSell

Nektar Therapeutics

Howard W Robin · President and CEO

$137K−2.0%Feb 18
NKTRSell

Nektar Therapeutics

John Northcott · SVP and Chief Commercial Officer

$53K−2.0%Feb 18
NKTRSell

Nektar Therapeutics

Gil M Labrucherie · SVP, COO and CFO

$83K−2.0%Feb 18
NKTRSell

Nektar Therapeutics

Gil M Labrucherie · SVP, COO and CFO

$316K−9.0%Nov 18
NKTRSell

Nektar Therapeutics

Jonathan Zalevsky · Chief R, D Officer

$275K−8.0%Nov 17
NKTRSell

Nektar Therapeutics

Mark Andrew Wilson · SVP and General Counsel

$86K−7.0%Nov 17
NKTRSell

Nektar Therapeutics

Jillian B. Thomsen · SVP and Chief Accounting Officer

$89K−4.0%Nov 17
NKTRSell

Nektar Therapeutics

Howard W Robin · President and CEO

$563K−8.0%Nov 17
NKTRSell

Nektar Therapeutics

John Northcott · SVP and Chief Commercial Officer

$80K−3.0%Nov 17
NKTRSell

Nektar Therapeutics

Myriam Curet · Director

$65K−12.0%Sep 24
NKTRSell

Nektar Therapeutics

Robert Chess · Director

$83K−2.0%Sep 24
NKTRSell

Nektar Therapeutics

Jeffrey Robert Ajer · Director

$65K−10.0%Sep 24
NKTRSell

Nektar Therapeutics

Robert Chess · Director

$293K−6.0%Sep 10
NKTRSell

Nektar Therapeutics

Jonathan Zalevsky · Chief R, D Officer

$106K−3.0%Aug 18
NKTRSell

Nektar Therapeutics

Mark Andrew Wilson · SVP and General Counsel

$26K−3.0%Aug 18
NKTRSell

Nektar Therapeutics

Howard W Robin · President and CEO

$159K−3.0%Aug 18
NKTRSell

Nektar Therapeutics

Jillian B. Thomsen · SVP and Chief Accounting Officer

$184K−9.0%Aug 18
NKTRSell

Nektar Therapeutics

John Northcott · SVP and Chief Commercial Officer

$86K−3.0%Aug 18
NKTRSell

Nektar Therapeutics

Gil M Labrucherie · SVP, COO and CFO

$149K−4.0%Aug 18
NKTRSell

Nektar Therapeutics

Robert Chess · Director

$96K−2.0%Jul 22
NKTRSell

Nektar Therapeutics

Jonathan Zalevsky · Chief R, D Officer

$569K−12.0%May 19

Filings come from SEC EDGAR within a minute of the SEC accepting them. Without Pro, each one unlocks 4 hours later. Not investment advice.

Questions

Where does the data come from?

Corporate insider trades come straight from SEC Form 4 filings, pulled from EDGAR within a minute of each filing. Congress trades come from STOCK Act disclosures. All of it is public and free to browse here, and Pro sees the newest filings first.

How often is it updated?

Every minute from 6 AM to 10 PM New York time on weekdays, the hours the SEC accepts filings. Pro sees each filing as it lands. Without Pro, a filing unlocks 4 hours after the SEC accepts it.

Is following insider trades legal?

Yes. Insiders are legally required to disclose their trades within a few days. Acting on those public disclosures is completely legal. Trading on private, non-public information is illegal, but that's a different thing.

What does the iPhone app add?

We're building an iPhone app that alerts you to new filings and, if you choose, copies a buy into your own brokerage after you approve it. It isn't out yet, and the waitlist is free.